Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1684 of 5804
-
New combo therapy shows promise for Tough-to-Treat lymphomas
Disease control OngoingThis phase I trial studies the side effects and best dose of BTK inhibitor PCI-32765 when given together with rituximab and bendamustine hydrochloride in treating patients with recurrent non-Hodgkin lymphoma (NHL). BTK inhibitor PCI-32765 may stop the growth of cancer cells by bl…
Phase: PHASE1 • Sponsor: Kami Maddocks, MD • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis phase Ib/II trial studies the side effects and best dose of trametinib and navitoclax and how well they work in treating patients with solid tumors that have spread to other places in the body (advanced or metastatic). Trametinib may stop the growth of tumor cells by blockin…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New drug shows promise for stopping deadly seizures
Disease control CompletedThe purpose of this study is to evaluate the safety and tolerability of SAGE-547 in participants in super-refractory status epilepticus (SRSE).
Phase: PHASE1, PHASE2 • Sponsor: Supernus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 26, 2026 17:02 UTC
-
New radiation technique aims to save implants in breast cancer patients
Symptom relief CompletedThe purpose of this study is to determine if a radiation treatment called "Multi-beam Intensity Modulated Radiation Therapy"(IMRT) can reduce side effects related to your implant if they are a candidate for radiation therapy. Currently, the standard method of giving radiation is …
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
New vaccine strategy aims to shield spleenless adults from deadly infections
⭐️ VACCINE ⭐️ CompletedEvaluate the immunogenicity of an innovative pneumococcal vaccination strategy in splenectomized adults comprising 1 dose of Prevenar13® conjugate vaccine (PCV) at M0 followed by 1 dose of Pneumo23® or Pneumovax® polysaccharide vaccine (PPSV) at M2. Duration of follow-up of 36 mo…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:58 UTC
-
New ankle implant tracked for 10 years: will it hold up?
Disease control OngoingThe primary objective of this study is to obtain implant survivorship and clinical outcome data for commercially available Zimmer Trabecular Metal Total Ankle implants used in primary or revision total ankle arthroplasty. The assessment will include implant survivorship and clini…
Phase: NA • Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Cancer drug shows promise for rare salivary gland tumor
Disease control CompletedRegorafenib is an oral medication that can interfere with cancer cell growth and reduce the growth of blood vessels around tumors. This study will help find out if regorafenib is a useful drug for treating patients with adenoid cystic carcinomas. Regorafenib has been approved by …
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 15:32 UTC
-
New HIV vaccine combos show promise in early trial
⭐️ VACCINE ⭐️ CompletedThe development of a safe and effective HIV-1 vaccine strategy would probably be the best solution for the ultimate control of the worldwide AIDS pandemic. Heterologous prime-boost immunisations are today considered promising HIV prophylactic vaccine strategies. It is thus releva…
Phase: PHASE1, PHASE2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:07 UTC
-
New pill targets genetic flaw in tough cancers
Disease control CompletedThe purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced solid tumors, including glioma, that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where c…
Phase: PHASE1 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug selinexor tested in kids with Tough-to-Treat leukemia
Disease control OngoingThis research study involves participants who have acute lymphoblastic or acute myelogenous leukemia that has relapsed or has become resistant (or refractory) to standard therapies. This research study is evaluating a drug called KPT-330. Laboratory and other studies suggest that…
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Experimental hepatitis b drug shows promise in early trial
Disease control TerminatedThe purpose of this study is to determine whether ARC-520 in combination with entecavir is effective in the treatment of patients with chronic HBV Infection.
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Brain implant offers sound hope for deaf children born without ears
Disease control CompletedCurrent treatment options for bilateral profoundly deaf children, diagnosed with inner ear anatomical abnormalities, are limited and, in the case of absent cochleas, non-existent. An auditory brainstem implant (ABI) places an electrode close to the auditory nucleus in the brainst…
Phase: PHASE1 • Sponsor: Laurie Eisenberg • Aim: Disease control
Last updated Jun 26, 2026 17:22 UTC
-
New shot may beat standard pill for chemo nausea
Symptom relief CompletedThe primary study objective is to demonstrate the superiority of APF530 500 mg given subcutaneously (SC) compared with ondansetron 0.15 mg/kg given intravenously (IV) (up to a maximum of 16 mg) in the delayed-phase (\> 24-120 hours) complete response (CR) rate (defined as no emes…
Phase: PHASE3 • Sponsor: Heron Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC
-
Blood-Derived injection may heal stubborn knee tendon pain — trial puts it to the test
Disease control CompletedThe goal of this study is to find an effective treatment for chronic patellar tendinopathy (PT). Investigators will conduct a 32-week randomized controlled clinical trial to determine whether platelet rich plasma (PRP) injections improve disease-specific clinical outcomes with co…
Phase: PHASE2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Gene therapy for inherited blindness passes early safety check
Disease control CompletedThe purpose of this study is to evaluate the safety and tolerability profile of ascending doses of GS010 in Leber Hereditary Optic Neuropathy (LHON) patients.
Phase: PHASE1, PHASE2 • Sponsor: GenSight Biologics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New PET scans could unmask hidden tumors in rare hormone disorder
Diagnosis Recruiting nowBetween 10% and 15% of patients with endogenous hypercortisolism (Cushing syndrome) have ectopic (non-pituitary) production of adrenocorticotropin hormone (ACTH) that causes cortisol excess. In approximately 50% of these patients, the tumoral source of ACTH cannot be found initia…
Phase: PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Diagnosis
Last updated Jul 10, 2026 00:00 UTC
-
Can your genes predict a brain aneurysm rupture?
Knowledge-focused Recruiting nowThe project will involve multiple units within our Institute (Neurosurgery, Cerebrovascular Diseases, Neurology IV), as well as additional neurosurgical centers across Italy, for the enrollment of patients with saccular intracranial aneurysms (sIA), both ruptured and unruptured. …
Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Ultrasound-Guided breathing support may cut ICU distress
Disease control CompletedProspective, randomized clinical multicentric study in ICU during weaning from mechanical ventilation.
Phase: PHASE3 • Sponsor: University Hospital, Clermont-Ferrand • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could arthritis drug humira ease rare skin disease?
Disease control CompletedThe main objective of this studies therapeutic : to determine the effect of Adalimumab (HumiraR) on clinical inflammatory manifestations of patients with Netherton syndrome after 3 months of treatment , with a post treatment period follow-up of 3 months. Second objectives are To…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New study tests if Same-Time radiation and chemo is safe for breast cancer
Disease control OngoingIn a small study at Johns Hopkins, women were treated with partial breast irradiation and chemotherapy given at the same time. We are now testing in a bigger study whether giving partial breast irradiation and chemotherapy at the same time (our new method) has the same side effe…
Phase: NA • Sponsor: Richard Zellars • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC